Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.3700+0.0400 (+1.72%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close2.3300
Open2.3500
Bid2.3200 x 4000
Ask2.4100 x 800
Day's Range2.3200 - 2.4000
52 Week Range1.0300 - 4.1500
Volume49,646
Avg. Volume189,724
Market Cap103.417M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-0.6800
Earnings DateMar 06, 2023 - Mar 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CTSO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cytosorbents Corporation
    Analyst Report: Illumina IncIllumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic analysis. The company's products and services are sold to genomic research centers, academic institutions, government and commercial laboratories, and hospitals, as well as to pharmaceutical, biotech, agrigenomics, and consumer genomics businesses. The company's portfolio of products and services are designed to accelerate and simplify genetic analysis. The company also invests in startup companies that are pursuing promising genomic-related opportunities. It has roughly 9,800 full-time employees. ILMN shares are included in the S&P 500 index.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • PR Newswire

    CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

    CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received regulatory approval from Health Canada allowing inclusion of Canadian sites into the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) randomized, controlled trial.

  • PR Newswire

    CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs

    CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has appointed Irina B. Kulinets, Ph.D., as Senior Vice President of Global Regulatory Affairs. Dr. Kulinets brings more than 30 years of experience in regulatory affairs and clinical research of medical devices, biologics, and combination products in multiple t

  • Simply Wall St.

    Can Cytosorbents (NASDAQ:CTSO) Afford To Invest In Growth?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Advertisement
Advertisement